Bac3Gel - About the company
Bac3Gel is a funded company based in Porto Salvo (Portugal), founded in 2019 by Daniela Pacheco and Sebastiao Van Uden. It operates as a Developer of human mucus models for drug discovery. Bac3Gel has raised an undisclosed amount in funding. The company has 95 active competitors, including 36 funded and 2 that have exited. Its top competitors include companies like InSphero, Pandorum and Ncardia.
Company Details
Developer of human mucus models for drug discovery. The Bac3Gel is a 3D substrate to culture, transport, preserve and deliver bacteria. It also recreates human microbiota in vitro for developing bacteria-modulating drugs, antimicrobial efficacy screening, and other applications.
- Website
- www.bac3gel.com/
- Email ID
- *****@bac3gel.com
Key Metrics
Founded Year
2019
Location
Porto Salvo, Portugal
Stage
Funding Raised
Latest Funding Round
Ranked
33rd among 95 active competitors
Employee Count
11 as on May 31, 2026
Sign up to download Bac3Gel's company profile
Bac3Gel's funding and investors
Bac3Gel has raised funding over 2 rounds. Its first funding round was on Jun 02, 2020. Its latest funding round was a Grant (prize money) round on 2022 for $*****. 1 investor participated in its latest round. Bac3Gel has 2 institutional investors.
Here is the list of recent funding rounds of Bac3Gel:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
2022 | 4684 | Grant (prize money) | 8028 | 2834 | 9856 | 4641 |
Jun 02, 2020 | 7043343 | Grant (prize money) | 9355137 | 8525173 | 1492063 |
Access funding benchmarks and valuations. Sign up today!View details of Bac3Gel's funding rounds and investors
Bac3Gel's founders and board of directors
Founder? Claim ProfileThe founders of Bac3Gel are Daniela Pacheco and Sebastiao Van Uden. Sebastiao Van Uden is the CEO of Bac3Gel.
Here are the details of Bac3Gel's key team members:
- Daniela Pacheco: Co-founder & CTO of Bac3Gel.
- Sebastiao Van Uden: Co-Founder & CEO of Bac3Gel.
View details of Bac3Gel's Founder profiles and Board Members
Bac3Gel's employee count trend
Bac3Gel has 11 employees as of May 26. Here is Bac3Gel's employee count trend over the years:
Uncover Bac3Gel's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Bac3Gel's Competitors and alternates
Top competitors of Bac3Gel include InSphero, Pandorum and Ncardia. Here is the list of Top 10 competitors of Bac3Gel, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  InSphero 2009, Schlieren (Switzerland), Series D | Developer of cell based assays for drug screening | $35M | 67/100 | |
2nd | Developer of regenerative medicine and 3D tissues | $51.4M | 65/100 | ||
3rd | Ncardia 2011, The Hague (Netherlands), Series C | Company offering hiPSC based products and services for drug discovery and development | $77.4M | 61/100 | |
4th | Newcells Biotech 2014, Newcastle Upon Tyne (United Kingdom), Series B | Developer of induced pluripotent stem cells derived organoid models for research application | $14.4M | 58/100 | |
5th |  Vivodyne 2021, Philadelphia (United States), Series A | Developer of AI-based platform for lab-grown human tissues | $118M | 44/100 | |
6th |  Parallel Bio 2020, Cambridge (United States), Series A | Limited information available | $25.4M | 56/100 | |
7th | Developer of stem-cell derived organoid models for cardiac drug discovery | $6.58M | 51/100 | ||
8th |  OncoPrecision 2020, Cordoba (Argentina), Seed | Developer of personalized assays for oncology precision therapy | $4.2M | 51/100 | |
9th |  Nextandbio 2019, Seoul (South Korea), Series A | Provider of organoid technology to develop customized treatments for patients | $5.27M | 48/100 | |
10th | Xilis 2019, Durham (United States), Series B | Developer of drug discovery and precision therapy platform for oncology | $116M | 44/100 | |
33rd | Developer of human mucus models for drug discovery | - | 31/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Bac3Gel's competitors? Click here to see the top ones
Bac3Gel's Investments and acquisitions
Bac3Gel has made no investments or acquisitions yet.
Are you a Founder ?
FAQs about Bac3Gel
Explore our recently published companies
- Bitolo - Tortola based, 2021 founded, Unfunded company
- BioLink Therapeutics - Bengaluru based, 2023 founded, Funding Raised company
- Bio-Combinator - Bengaluru based, 2023 founded, Funding Raised company
- Kentas Last & Schakt - Sweden based, 1985 founded, Public company
- Mehrotra Diagnostics - Kanpur based, Unfunded company
- Ikaros Solskydd - Sweden based, 2007 founded, Public company
